26 results
8-K
EX-99.1
ANNX
Annexon Inc
13 May 24
Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones
4:05pm
to block C1q and the entire classical complement pathway in both the body and the brain.
Hosted an R&D Day on GBS that covered its serious unmet need … to host an R&D Day on GA and therapeutic potential of ANX007 in mid-2024.
ANX1502 in CAD: POC trial evaluating the pharmacodynamics and efficacy
8-K
EX-99.1
ANNX
Annexon Inc
26 Mar 24
Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones
4:05pm
ventilation.
Hosted an R&D Day on the burden of disease, current treatment paradigm and market opportunity for GBS in March 2024.
ANX007 in GA: First-in-class … .
Research and development (R&D) expenses: R&D expenses were $23.3 million for the quarter ended December 31, 2023, and $113.8 million for the year ended
8-K
EX-99.1
ANNX
Annexon Inc
4 Mar 24
Regulation FD Disclosure
5:25pm
Exhibit 99.1 Virtual R&D Day | March 1, 2024 Nasdaq: ANNX
Guillain-Barré Syndrome: A Focus on its Serious Unmet Need and Annexon’s Novel Therapeutic
8-K
hk2sx1s59t 3nzr0
4 Mar 24
Regulation FD Disclosure
5:25pm
8-K
EX-99.1
0ex96 rxn0b32
13 Nov 23
Annexon Reports Significant Progress with its Priority Programs and Third Quarter 2023 Financial Results
4:10pm
8-K
EX-99.1
7mkdp6vgeks246zjc
7 Aug 23
Annexon Highlights Recent Pipeline and Business Progress and Reports Second Quarter 2023 Financial Results
4:12pm
8-K
EX-99.1
zchee4hp
8 May 23
Annexon Reports First Quarter 2023 Financial Results and Highlights Recent Pipeline Progress
4:11pm
8-K
EX-99.1
a4uiycwu
3 Nov 22
Annexon Reports Third Quarter 2022 Financial Results and Plans to Provide Updates on Complement Therapeutic Portfolio in January 2023
6:45am
8-K
EX-99.1
85dq3leq36katnu8qex7
8 Aug 22
Annexon Biosciences Highlights Business and Portfolio Progress and Key Anticipated Milestones and Reports Second Quarter 2022 Financial Results
4:30pm
8-K
EX-99.1
fmuq7l0h064
9 May 22
Annexon Biosciences Highlights Portfolio Progress and Key Anticipated Milestones, and Reports First Quarter 2022 Financial Results
4:20pm
8-K
EX-99.1
wao 0d9rc0p7
9 Nov 21
Annexon Biosciences Announces Business and Program Highlights and Reports Third Quarter 2021 Financial Results
4:16pm
8-K
EX-99.1
uer21
16 Aug 21
Annexon Biosciences Reports Second Quarter 2021 Financial Results and Provides Mid-Year Business Update
4:11pm
8-K
EX-99.1
cq8 b7dt8b
22 Jul 21
Regulation FD Disclosure
4:15pm
8-K
EX-99.1
g6n0z49qhsdyasvyhus8
17 May 21
Annexon Biosciences Provides Business Update and Reports First Quarter 2021 Financial Results
4:17pm
8-K
EX-99.1
kbh8pl
25 Mar 21
Annexon Biosciences Reports Fourth Quarter and Full-Year 2020 Financial Results
7:20am
10-K
b8to0lmxu0v9sq u6x
25 Mar 21
Annual report
7:16am